Skip to content

No results found

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

CARM Carisma Therapeutics, Inc. Common Stock
$0.04 0.00% 0.00
Notify me if price changes either direction
Interactive Brokers Logotype

Buy CARM stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 1.5M
Enterprise value -466732
Trailing PE 0.19473685
Forward PE -0.04065934
PEG Ratio -0.0004374523442029
Enterprise to EBITDA -0.033
Enterprise to revenue -0.009
Price to book MRQ -1.7833443736172
Price to sales TTM 0.029416857

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 52.6M
EBITDA 14.2M
Diluted EPS TTM 0.19
Total Cash (MRQ) 2.8M
Current ratio (MRQ) 0.862
Operating Cash Flow (TTM) -22415000

CARM trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent CARM News

Home

No results found

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.